Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-DPB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-DPB1/HLA-DPA1 Monomer / Heterodimer Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Available in allele-specific variants (e.g., *04:01, *04:02). |
View HLA-DPB1 Products |
| Gene Delivery | HLA-DPB1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to present target antigens. |
View HLA-DPB1 Products |
| Benchmark Ab | Anti-HLA-DPB1 Recombinant Antibody Recombinant positive control for flow cytometry and IHC validation. |
View HLA-DPB1 Products |
| Validator | HLA-DPB1 siRNA Set For knockdown verification in antigen presentation assays. |
View HLA-DPB1 Products |
| Related Target A | HLA-DPA1 The alpha chain partner required to form the functional HLA-DP heterodimer complex. |
View HLA-DPA1 Products |
| Related Target B | MAGE-A3 Tumor-associated antigen frequently presented by HLA-DPB1*04:01 in TCR-T therapies. |
View MAGE-A3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allele-specific cross-reactivity screening (e.g., *04:01 vs *04:02) | Sequence-verified recombinant proteins covering major clinical alleles with high purity (>95%) |
| MHC Class II Heterodimer instability in vitro | Co-expressed HLA-DPA1/DPB1 stable heterodimers or single-chain trimers (peptide-linker-beta-linker-alpha) |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HLA-DPB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-DPB1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to TCR-T therapies and TCR-like bispecifics. As first-generation immunotherapies reach the clinic, the next wave of R&D is targeting highly prevalent alleles (such as HLA-DPB1*04:01 and *04:02) to treat solid tumors via tumor-associated antigen presentation. Additionally, HLA-DPB1 mismatching remains a critical focus in optimizing outcomes for allogeneic hematopoietic stem cell transplantation (HSCT) and mitigating Graft-versus-Host Disease (GvHD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Therapy | Adaptimmune, Immatics, GSK | Solid Tumors (Melanoma, Synovial Sarcoma) | Allele-specific binding assays (Need high-purity HLA-DPB1/DPA1 monomers) |
| TCR-like Antibodies / Bispecifics | Immunocore, Roche | Oncology, Infectious Diseases | Heterodimer Validation (Need native conformation HLA-DP complex) |
| Cell Therapy / HSCT Diagnostics | One Lambda, Immucor | GvHD Prevention, Transplant Rejection | High-throughput screening panel (Need sequence-verified polymorphic proteins) |